Sun Pharma Launches Ready-to-Infuse INFUGEM In U.S.

(RTTNews) - Sun Pharmaceutical Industries Ltd. (SUNPHARMA, 524715) announced that INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the U.S.

INFUGEM is the first chemotherapy product that comes in a premixed, ready-to-infuse formulation. It was approved by the U.S. Food and Drug Administration or FDA in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer.

INFUGEM is an alcohol-free, clear, colorless, sterile solution of 10mg/mL gemcitabine in 0.9% sodium chloride that is supplied to pharmacists in ready-to-infuse bags as a Spike & Go package.

It is the only available gemcitabine formulation that does not require reconstitution and syringe withdrawal prior to intravenous administration. Eliminating these steps reduces complexity and minimizes the inherent risks of hazardous drug exposure, contamination, and medication errors, the company noted.

The company noted that INFUGEM is the first product using Sun's proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in ready-to-infuse final dosage bags.